Tiziana Life Sciences Ltd Com SEC Filings

Tiziana Life Sciences LTD reported that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease. This milestone comes shortly after enrollment began, when the first patient was expected to be dosed imminently. The Phase 2 study is evaluating intranasal foralumab both as a standalone treatment and in combination with FDA-approved anti-amyloid therapies lecanemab (Leqembi) or donanemab in early Alzheimer’s patients.

Tiziana Life Sciences LTD reported that its Chief Executive Officer, Ivor Elrifi, bought 163,400 shares of Tiziana common stock in the open market on December 15, 2025. These purchases increase his total open-market purchased holdings to 357,848 shares.

This move means the company’s top executive has committed more of his own capital to Tiziana’s stock, which some investors view as a sign of confidence in the business. The disclosure is provided in a Form 6-K, with an accompanying press release furnished as Exhibit 99.1.

Tiziana Life Sciences LTD filed a Form 6-K stating that it has withdrawn its proposed public offering of common shares due to market conditions.

The company furnished a press release dated December 15, 2025 as Exhibit 99.1, and specified that this material is being furnished, not deemed filed or automatically incorporated into other securities law filings.

Tiziana Life Sciences Ltd. is conducting a primary best-efforts offering of common shares on Nasdaq to raise cash for its clinical-stage neurology pipeline. ThinkEquity LLC is acting as exclusive placement agent, but is not required to place any minimum number of shares, there is no minimum offering amount and no escrow account, so any funds received will be available to the company immediately.

The company plans to use net proceeds, together with existing cash, mainly to advance its lead candidate foralumab in non-active secondary progressive multiple sclerosis, Alzheimer’s disease and multiple system atrophy, and for working capital, capital spending and general corporate purposes. Because the offering price will be above the company’s net tangible book value, new investors are expected to incur immediate and substantial dilution, and future equity or debt financings could create additional dilution or restrictions. The prospectus also highlights volatility in TLSA’s share price and the likelihood that Tiziana will need further capital even after this offering.

Tiziana Life Sciences LTD reports that enrollment has begun in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease. The study is testing intranasal foralumab, an experimental therapy, both on its own and together with FDA‑approved anti‑amyloid drugs lecanemab or donanemab.

The company plans to dose the first patient next week, indicating the trial is moving from screening into active treatment. Baseline clinical assessments, cognitive testing, TSPO‑PET brain imaging, and fluid biomarker measurements have already been completed for the first participants, laying the groundwork to track how patients respond over time.

Tiziana Life Sciences (TLSA) reported that its Phase 2 clinical trial of intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham. This places the company’s ALS study within a coordinated clinical research framework focused on the disease. The update is structured as an informational report and does not include financial results or transaction details.

Tiziana Life Sciences (TLSA) furnished a Form 6-K stating its senior leadership will present a corporate overview at the Jefferies London Healthcare Conference. Chief Executive Officer Ivor Elrifi and Chief Operating Officer/Chief Financial Officer Keeren Shah will highlight the company’s innovative pipeline and recent clinical milestones.

The accompanying press release is included as Exhibit 99.1. The information is furnished, not filed, under the Exchange Act and is not incorporated by reference except as specifically stated.

Tiziana Life Sciences (TLSA) announced it will participate as a presenting company at BIO-Europe 2025, described as Europe’s premier life sciences partnering conference.

The event will be held November 3–5, 2025, at the Vienna Exhibition and Congress Center (Messe Wien) in Vienna, Austria. The related press release was furnished as Exhibit 99.1 and is not deemed filed under Section 18 of the Exchange Act.